Loading…

Medical Research Finder

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Interleukin-33 (IL-33)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Transcription factor 7 (T-cell specific, HMG-box) (TCF7) expressing CD8+ Cytotoxic T Lymphocytes (CTLs) can self-renew like stem cells, a key for immune defense against chronic viral infections and cancer. A decisive factor for this property is interleukin-33 (IL-33).
Marx et al. 2023 Immunity 56: 813–828

Interleukin-33 (IL-33), part of the Interleukin-1 (IL-1) / Interleukin-1 family, is crucial for driving protective [CD8+ T cell](brain://s-pKF05-6k…

Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 + T-cell responses to acute and chronic viral infection
Aparicio-Domingo et al. 2021 Eur J Immunol 51: 76-90
IL-33 augments virus-specific memory T cell inflation and potentiates the efficacy of an attenuated cytomegalovirus-based vaccine
McLaren et al. 2019 J Immunol 202: 943-955
IL-33 in T cell differentiation, function, and immune homeostasis
Peine et al. 2016 Trends Immunol 37: 321-333
Review
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8 + T cells
Yang et al. 2011 Eur J Immunol 41: 3351-3360
Interleukin-33 reinvigorates antiviral function of viral-speciﬁc CD8 + T Cells in Chronic Hepatitis B Virus Infection
Li et al. 2022 Viral Immunol 35: 41-49
Overview of the IL-1 family in innate inflammation and acquired immunity
Dinarello 2018 Immunol Rev 281: 8-27
Review
Replicating viral vector platform exploits alarmin signals for potent CD8(+) T cellmediated tumour immunotherapy
Kallert et al. 2017 Nat Commun 8: 15327

12/16/2025